Table 2.
Comparison of clinical efficacy and outcomes between the two groups.
| Variables | All (n = 86) |
Combination (n = 35) |
Remdesivir Alone (n = 51) |
p-Value |
|---|---|---|---|---|
| Clinical efficacy of treatment: | ||||
| -Time for fever resolution of <37 °C of at least 24 h, median (IQR), n = 82 | 37.0 (21.0–76.1) | 27.5 (21.2–60.2) | 56.5 (20.5–90.7) | 0.02 |
| -Afebrile within 48 h, n = 82 | 43 (52.4) | 20 (71.4) | 23 (46) | 0.03 |
| -Afebrile within 72 h, n = 82 | 57 (69.5) | 26 (92.8) | 31 (62) | <0.01 |
| -Increase in Ct value of >3 after initiating treatment | 53 (61.6) | 28 (80) | 25 (49) | <0.01 |
| -Increase in Ct value of >5 after initiating treatment | 48 (55.8) | 27 (77.1) | 21 (41.1) | <0.01 |
| Outcomes: | ||||
| -COVID-19 exacerbation (requiring oxygen after initiating treatment) | 3 (3.5) | 0 | 3 (5.9) | 0.22 |
| -Death by COVID-19 | 2 (2.3) | 0 | 2 (3.9) | 0.32 |
| -30-day all-cause mortality | 8 (9.3) | 2 (5.7) | 6 (11.7) | 0.34 |
COVID-19, coronavirus disease; IQR, interquartile range.